# Two Sigma Investments LP

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/two-sigma-investments-lp
Canonical HTML page: https://getbiobrief.com/entity/two-sigma-investments-lp

## Timeline

- **2026-08-14**: Quarterly earnings release — Lantern Pharma reported quarterly EPS of ($0.57), missing consensus by $0.19; shares rose $0.02 to $2.65.
- **2026-07-29**: Weiss Ratings upgrade — Weiss Ratings upgraded Lantern Pharma from 'sell (e+)' to 'sell (d-)'.
- **2026-05-23**: Wall Street Zen rating action — Research note on LTRN reported with conflicting direction across sources (upgrade to hold vs downgrade to sell).

## Recent coverage (1 stories)

### Lantern Pharma Posts $0.57 Loss, Misses Consensus by $0.19; Sell Rating Stands
2026-08-16 16:14:45 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Lantern Pharma's $0.57 quarterly loss missed consensus by $0.19, underscoring clinical-stage risk. The micro-cap oncology company has no product revenue, and analysts maintain a Sell rating. Biotech investors need clarity on cash runway and upcoming trial catalysts.
Full story: https://getbiobrief.com/story/lantern-pharma-clinical-stage-eps-miss

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.